Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
4(36%)
Results Posted
40%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
2
18%
Ph not_applicable
1
9%
Ph phase_4
4
36%
Ph phase_3
2
18%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
4(44.4%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Recruiting4
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (22.2%)
Phase 32 (22.2%)
Phase 44 (44.4%)
N/A1 (11.1%)

Trials by Status

terminated19%
recruiting436%
completed545%
withdrawn19%

Recent Activity

4 active trials
Showing 5 of 11
recruitingphase_2

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383
recruitingphase_2

Advanced Imaging for Pulmonary Fibrosis

NCT06532071
completedphase_4

Dotarem vs Gadobutrol Contrast for Breast MRI

NCT03730051
recruitingphase_4

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT04373564
completedphase_3

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

NCT05915728
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07572383Phase 2

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

Recruiting
NCT06532071Phase 2

Advanced Imaging for Pulmonary Fibrosis

Recruiting
NCT03730051Phase 4

Dotarem vs Gadobutrol Contrast for Breast MRI

Completed
NCT04373564Phase 4

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
NCT05915728Phase 3

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

Completed
NCT05937776

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

Recruiting
NCT05915702Phase 3

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

Completed
NCT03091803

QSM and Regional DCE MRI Permeability Using GOCART Technique

Withdrawn
NCT01806740Phase 4

DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC

Terminated
NCT01254552Phase 4

Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis

Completed
NCT03000036Not Applicable

Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11